ArticleJournal of biochemical and molecular toxicology2025
Taurine Mitigates Metaflumizone-Induced Hepatonephrotoxicity in Rats by Inhibiting Oxidative Stress, Inflammation, and Apoptosis.
Article in Journal of biochemical and molecular toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Metaflumizone (MTF) is a pyrazoline sodium channel blocker (SBI) insecticide, and data on its toxicity are limited. Taurine (2-aminoethanesulfonic acid) is a sulfur-containing β-amino acid that is naturally found in high concentrations in cells. In this study, we thoroughly evaluated the impact of taurine on MTF-induced hepatonephrotoxicity in a rat model, focusing on oxidative stress, inflammatory responses, and programmed cell death. In the present study, MTF (500 mg/kg, orally) to induce hepatonephrotoxicity was delivered to male rats for 30 days, and taurine at different concentrations (50, 100, and 200 mg/kg, orally) was used for protective effect for the same period. Taurine treatment alleviated the elevated levels of AST, ALT, ALP, BUN, and creatinine caused by MTF. It further suppressed malate dehydrogenase levels and enhanced antioxidant defense by elevating SOD, GSH, and CAT levels. Additionally, taurine increased the mRNA expression levels of Bcl-2, which had been reduced due to oxidative stress, inflammatory, and apoptotic pathways, while suppressing the elevated gene expression levels of NFκB, TNF-α, Bax, and Cas-3. Furthermore, taurine regulated the altered protein expression levels of Bcl-2, Bax, and TNF-α induced by MTF. Microscopically, taurine also mitigated liver and kidney tissue damage caused by MTF. In conclusion, taurine significantly reduced MTF-induced hepatonephrotoxicity by suppressing oxidative stress, inflammatory responses, and programmed cell death. These findings indicate that taurine has the potential to be a treatment option in the case of the prevention of liver and kidney damage caused by SBI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.